The people building genome-driven AMR care.
A clinical and computational team, the institutions backing us, and the roadmap ahead.
Scientists, engineers, and clinicians — building precision AMR diagnostics.
Different expertise. One system. One company. BactoAI is a multidisciplinary team building one AMR intelligence platform — the product, models, and technology belong to the company, and each of us leads a defined part of it.
Biotechnology researcher at Kenyatta University with hands-on analytical experience from a Kenya Bureau of Standards attachment in gravimetry, titrimetry, spectroscopy, and related laboratory methods. An alumnus of the NextGen Antimicrobial Stewards Initiative and 2nd-place finisher at Kenyatta University's Research in Science bootcamp, where BactoAI was first pitched.
Leads BactoAI's vision, scientific direction, partnerships, and strategic growth — representing the company with hospitals, universities, funders, and antimicrobial stewardship networks across East Africa.
Software engineer responsible for BactoAI's technology infrastructure and product development.
Leads the engineering architecture, cloud systems, and development workflows that transform BactoAI's scientific models and data pipelines into reliable, scalable software products.
Electrical engineer specialising in applied machine learning and predictive analytics.
Leads the development, training, evaluation, and optimisation of BactoAI's machine-learning systems, working closely with the wider team to translate scientific and clinical requirements into reliable predictive tools.
Leads BactoAI's day-to-day operations, pilot coordination, project execution, and organisational systems.
Connects the scientific, engineering, and partnership functions to ensure that projects move efficiently from development to real-world implementation.
Advisors & Partners
Bringing the AMR conversation to national television.
BactoAI founder Samwel Elegwa joined KUTV Kenya’s Art & Culture Monday to talk about antimicrobial resistance and why faster, genome-driven diagnostics matter for patients, clinicians, and public health systems.
“AMR is not just a lab problem — it is a public health emergency that needs to be part of everyday conversation.”
Samwel with Hassan Lewa at the KUTV studio after the Art & Culture Monday interview.
Representing BactoAI at the BIK Ventures Hub pitch event.
In May 2026, Samwel Elegwa and William Otieno represented BactoAI at the BIK Ventures Hub startup pitch event at Kenyatta University — a landmark competition bringing together founders, investors, and industry leaders. The event was covered in print and on BIK’s YouTube channel.
Press coverage of the BIK Ventures Hub pitch event at Kenyatta University, where BactoAI took the stage among East Africa’s emerging startups.
Samwel shares his feedback on the BIK Ventures experience and what it means for startups building in East Africa.
BIK’s recap video features the event’s innovations, including BactoAI.
Backed by research and innovation networks.
Built alongside leading universities, medical research institutes and technology partners across East Africa and the UK.
Let's build the AMR response of the next decade — together.
We work with hospitals, sequencing providers, public-health agencies and academic groups. Tell us about your work and we'll respond within 2 business days.
- · Access to our validation pipeline
- · Co-authored clinical studies
- · Custom AMR reports for your isolates
- · Deployment support in low-resource labs
Trusted by clinicians and researchers on the front lines of AMR.
Feedback from pilot partners across East African hospitals, research consortia, and public-health teams.
"The turnaround difference is night and day. In our pilot ward, we had a resistance profile in hand before the culture even reached the incubator."
Pilot-participant feedback. Names and affiliations disclosed with permission at contract signing.
From prototype to regional platform.
Represented BactoAI at Kenyatta University's startup pitch showcase, with coverage in print and on BIK's channels.
Working AI pipeline with initial antibiotic models.
Secure, scalable, browser-based platform.
Deployments with clinical partners in East Africa.
Prospective studies on real clinical isolates.
Engagement with regulatory bodies for clinical use.
General availability for laboratories and hospitals.
Regional rollout & AMR surveillance partnerships.